Italia markets closed

CNTA Oct 2024 15.000 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
1,95000,0000 (0,00%)
Alla chiusura: 09:30AM EDT
Schermo intero
Chiusura precedente1,9500
Aperto1,9500
Denaro0,0000
Domanda2,0000
Prezzo d'esercizio15,00
Scadenza2024-10-18
Min-Max giorno1,9500 - 1,9500
Contratto - Min-MaxN/D
Volume1
Open Interest15
  • GlobeNewswire

    Centessa Pharmaceuticals Announces Additions to Senior Leadership Team

    BOSTON and LONDON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the appointment of April Dovholuk and Ellie Im, MD to Centessa’s executive team as Senior Vice President of Development Operations and Senior Vice President of Clinical Development, Oncology, respectively. In these newly created roles, Ms. Dovholuk will lead bot

  • GlobeNewswire

    Centessa Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

    BOSTON and LONDON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the Morgan Stanley 21st Annual Global Healthcare Conference, including a fireside chat on Tuesday, September 12, 2023 at 4:15 p.m. ET. The live webcast of this event, as well as an archived recording, will be availa

  • GlobeNewswire

    Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress

    Oral presentation to include preclinical profile for ORX750, Centessa’s first orexin agonist development candidate for the treatment of narcolepsy and other sleep disordersBOSTON and LONDON, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced that preclinical data for ORX750, its first orexin agonist development candidate, will